TAK 079

Drug Profile

TAK 079

Alternative Names: TAK079

Latest Information Update: 13 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 11 Nov 2016 Pharmacodynamics data from a preclinical study in Systemic lupus erythematosus presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP - 2016)
  • 01 Apr 2016 Takeda completes a phase I trial in Healthy volunteers in the United Kingdom (NCT02219256)
  • 01 Aug 2015 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top